Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study.

Leung K, Lipsitch M, Yuen KY, Wu JT.

Lancet Infect Dis. 2017 Mar;17(3):339-347. doi: 10.1016/S1473-3099(16)30465-0. Epub 2016 Dec 1.

PMID:
27914853
2.

Risk of resistant avian influenza A virus in wild waterfowl as a result of environmental release of oseltamivir.

Gillman A.

Infect Ecol Epidemiol. 2016 Oct 11;6:32870. doi: 10.3402/iee.v6.32870. eCollection 2016. Review.

3.

The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding.

Mohr PG, Deng YM, McKimm-Breschkin JL.

Virol J. 2015 Apr 22;12:67. doi: 10.1186/s12985-015-0295-3.

4.

Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan.

Takashita E, Kiso M, Fujisaki S, Yokoyama M, Nakamura K, Shirakura M, Sato H, Odagiri T, Kawaoka Y, Tashiro M.

Antimicrob Agents Chemother. 2015 May;59(5):2607-17. doi: 10.1128/AAC.04836-14. Epub 2015 Feb 17.

5.

Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium.

Burnham AJ, Armstrong J, Lowen AC, Webster RG, Govorkova EA.

J Virol. 2015 Apr;89(8):4575-87. doi: 10.1128/JVI.02473-14. Epub 2015 Feb 11.

6.

Antiviral drug profile of human influenza A & B viruses circulating in India: 2004-2011.

Potdar VA, Dakhave MR, Kulkarni PB, Tikhe SA, Broor S, Gunashekaran P, Chawla-Sarkar M, Abraham A, Bishwas D, Patil KN, Kadam AA, Kode SS, Mishra AC, Chadha MS.

Indian J Med Res. 2014 Aug;140(2):244-51.

7.

Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal.

Barrett S, McKimm-Breschkin JL.

Antiviral Res. 2014 Aug;108:30-5. doi: 10.1016/j.antiviral.2014.05.006. Epub 2014 May 20.

8.

Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Burnham AJ, Baranovich T, Marathe BM, Armstrong J, Webster RG, Govorkova EA.

Antimicrob Agents Chemother. 2014 May;58(5):2718-30. doi: 10.1128/AAC.02628-13. Epub 2014 Feb 24.

9.

Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.

Okomo-Adhiambo M, Nguyen HT, Abd Elal A, Sleeman K, Fry AM, Gubareva LV.

Influenza Other Respir Viruses. 2014 Mar;8(2):258-65. doi: 10.1111/irv.12215. Epub 2013 Dec 2.

10.

Comparative dynamics and distribution of influenza drug resistance acquisition to protein m2 and neuraminidase inhibitors.

Garcia V, Aris-Brosou S.

Mol Biol Evol. 2014 Feb;31(2):355-63. doi: 10.1093/molbev/mst204. Epub 2013 Nov 7.

11.

Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Burnham AJ, Baranovich T, Govorkova EA.

Antiviral Res. 2013 Nov;100(2):520-34. doi: 10.1016/j.antiviral.2013.08.023. Epub 2013 Sep 4. Review.

12.

Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic.

Hall RJ, Peacey M, Ralston JC, de Joux DJ, Bocacao J, Nicol M, Ziki M, Gunn W, Wang J, Huang QS.

Western Pac Surveill Response J. 2012 Oct 30;3(4):71-7. doi: 10.5365/WPSAR.2012.3.3.002. Print 2012 Oct.

13.

Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.

Yen HL, McKimm-Breschkin JL, Choy KT, Wong DD, Cheung PP, Zhou J, Ng IH, Zhu H, Webby RJ, Guan Y, Webster RG, Peiris JS.

MBio. 2013 Jul 16;4(4). pii: e00396-13. doi: 10.1128/mBio.00396-13.

14.

Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.

Takashita E, Fujisaki S, Kishida N, Xu H, Imai M, Tashiro M, Odagiri T; Influenza Virus Surveillance Group of Japan.

Influenza Other Respir Viruses. 2013 Nov;7(6):1390-9. doi: 10.1111/irv.12132. Epub 2013 Jun 8.

15.

Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

McKimm-Breschkin JL.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:25-36. doi: 10.1111/irv.12047. Review.

17.

Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.

Wong DD, Choy KT, Chan RW, Sia SF, Chiu HP, Cheung PP, Chan MC, Peiris JS, Yen HL.

J Virol. 2012 Oct;86(19):10558-70. doi: 10.1128/JVI.00985-12. Epub 2012 Jul 18.

18.

Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.

Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV.

Viruses. 2010 Oct;2(10):2269-89. doi: 10.3390/v2102269. Epub 2010 Oct 13. Erratum in: Viruses. 2011 Aug;3(8):1415-6.

19.

Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards.

Järhult JD, Muradrasoli S, Wahlgren J, Söderström H, Orozovic G, Gunnarsson G, Bröjer C, Latorre-Margalef N, Fick J, Grabic R, Lennerstrand J, Waldenström J, Lundkvist A, Olsen B.

PLoS One. 2011;6(9):e24742. doi: 10.1371/journal.pone.0024742. Epub 2011 Sep 12.

20.

Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses.

Barrett S, Mohr PG, Schmidt PM, McKimm-Breschkin JL.

PLoS One. 2011;6(8):e23627. doi: 10.1371/journal.pone.0023627. Epub 2011 Aug 17.

Supplemental Content

Support Center